US · Healthcare · Biotechnology
EPS came in at -0.37 against a street estimate of -0.72 — a beat of 48.6%.
Analysts rate Vanda Pharmaceuticals Inc a strong buy (4 buy, 1 hold, 0 sell out of 5) with an average price target of $11.50.
MIXED Q3 revenue grew strongly, led by Fanapt and favorable HETLIOZ stocking, while losses remained substantial. NEREUS is scaling, BYSANTI launches in Q4, and Quimilza could launch in first-half 2027 if approved. Q3 FY26 No geographic revenue breakdown was discussed. Analysts focused on launch timing, clinical development, label expansion, pricing, reimbursement, and product conversion. Management emphasized preparation, ongoing enrollment, regulatory discussions, and uncertainty around FDA decisions. 2026-10-28…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 12.66% |
| State Street Corp | 5.82% |
| AQR Capital Management LLC | 5.78% |
| Renaissance Technologies Corp | 5.69% |
| Vanguard Capital Management, LLC | 4.17% |
| AIGH Capital Management, LLC | 3.38% |
| Acadian Asset Management LLC | 3.17% |
| Dimensional Fund Advisors, Inc. | 2.86% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Vanda Pharmaceuticals Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.